Tarsus Q1 Review: Strong Earnings, But Wall Street Wanted A Guidance Raise
Tarsus Pharmaceuticals Inc TARS
$62.48
▼ -4.14%
($-2.70)
Open
$65.00
Prev Close
$65.18
Day Range
$61.94 – $65.98
52W Range
$38.51 – $85.25
Market Cap
$2.69B
Beta
0.55
EPS (TTM)
$-1.13
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2020-10-16 |
| Shares Out. | 42,560,000 |
| Website | tarsusrx.com/ ↗ |
| Phone | 13025310855 |
Tarsus Pharmaceuticals Inc is a publicly traded company under the ticker symbol TARS on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
15 analysts (2026-05-01)
📰 Latest News for TARS
Tarsus and John Cena partner to raise awareness of Demodex blepharitis, a common eyelid disease affecting approximately 25 million Americans
Tarsus Pharmaceuticals Collaborates With John Cena Over Eyelid Disease Demodex Blepharitis
Tarsus Pharmaceuticals, Inc. (TARS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Transcript : Tarsus Pharmaceuticals, Inc. Presents at Bank of America Global Healthcare Conference 2026, May-12-2026 03
Tarsus to Participate in Upcoming Investor Conferences
Tarsus Pharmaceuticals, Inc. 2026 Q1 - Results - Earnings Call Presentation
Tarsus Pharmaceuticals Inc (NASDAQ:TARS) Beats Q1 Estimates with Explosive XDEMVY Growth But Stock Slips